Aragen offers choice of CLD platforms, efficient Upstream and Downstream process development.
CHO CLD platforms
CHO DG44, CHO GS, CHOZN, SP 2/0
Our CHO DG44 platform achieves >4g/L in 5 months, while CHO GS reaches up to 8g/L, with no royalties or milestone payments. Ideal for difficult proteins, NBEs, and animal health.
Over 100 CLD programs Pre-IND/GMP
Over 14 in clinical development and 3+ commercial production.
Key Attributes
RapTr2022 with Aragen o ers choice of CLD platforms
Royalty-free CHO DG44 best suited for biosimilar development.
Royalty free, accelerated timeline for DG44 and CHO GS (16 weeks from transfection to RCB)
Transfection to single cell clone evaluation in 16 weeks with Aragen’s optimized process
Our CLD platform uses a chemically defined serum free medium and proof of clonality to support IND filing
Strong Analytical capabilities – early engagement to establish quality and select right clones to advance
Aragen’s Process Development Solutions for Biologics CHO CLD Platforms
Aragen offers coefficient upstream and downstream process development
We use commercially available, nonproprietary media and feed for screening studies, allowing seamless transfer to any CDMO
Media and feed screening in shake flasks
Process parameter screening and optimization in AMBR250®
Process consistency and scalability happens in 1L, 5L & 10L bioreactor
Downstream Process Development
Key Attributes
Ambr250® platform for upstream process development- synergies to reduce time to IND
Fully automated AMBR250® 24 units, integrated to NOVA Flex-2 & Vi-Cell
Multifactorial DOE to screen process parameters like- pH, DO, Temp, agitation etc
Process parameter optimization and identifying best operative parameters
History of generating biosimilar cell lines- now in market
